J. Dormer Stephen Appointed to BioCT Board

Dormer Stephen, Co-Chair of Shipman & Goodwin’s Business and Finance Practice Group, has been appointed by BioCT to serve on the organization’s Board of Directors. BioCT works to expand Connecticut’s bioscience industry by bringing together companies, institutions, entrepreneurs, investors, government and service providers to support innovation, collaboration, education and advocacy.

Mr. Stephen has been an active member of BioCT (formerly CURE) and joins a group of directors highly qualified in the biotechnology, pharmaceuticals, health care, venture capital, finance and legal industries. In his practice, Mr. Stephen represents Fortune 500 companies, private equity funds, emerging companies and investment banks in the full range of venture capital and private equity and debt transactions, as well as in mergers, acquisitions and joint ventures. He has extensive experience handling sophisticated transactions for biotechnology, life sciences, medical products and health care technology companies. He also represents public and private clients in the capacity as outside general counsel, which includes advising them on strategic initiatives (such as joint ventures, joint development projects and intellectual property licensing and collaboration) and commercial contract matters.

Mr. Stephen is a frequent panelist and moderator at bioscience industry events. He has been ranked by Chambers USA in the area of Corporate M&A for the past five years, and has been listed among The Best Lawyers in America for Mergers and Acquisitions Law for the past two years.